Precision Epigenomics focuses on addressing cancer by targeting epigenetic changes (i.e., DNA methylation) that drive tumor development, progression, and treatment resistance. While genetic mutations have long been a focus in oncology, epigenetic dysregulation plays a critical role in how cancer cells behave, adapt, and evade therapy. Their work centers on using their understanding of DNA methylation to develop new and innovative diagnostic tests to detect cancer earlier.
The Health Challenge Precision Epigenomics Is Addressing:
Precision Epigenomics is committed to transforming healthcare by working to make life-saving, affordable multi-cancer early detection (MCED) technology accessible worldwide. Their mission is centered on detecting the deadliest cancers at their earliest stages through accessible EPISEEK® blood tests, using advanced epigenetic technology to help improve patient outcomes and reduce the impact of delayed diagnosis.
Cancer remains one of the leading causes of death worldwide, affecting millions of patients each year. Many cancers are diagnosed at a late stage, when treatment approaches are limited, and outcomes can be more difficult for patients. Diagnosing cancer at an earlier stage can open up more treatment options for patients and save lives, which is why earlier detection continues to be an important focus in oncology.
How Precision Epigenomics Is Making an Impact:
Precision Epigenomics is developing advanced epigenomic technologies that provide new diagnostic tools for cancer detection. Their goal is to help clinicians and researchers move beyond traditional diagnostic approaches and toward treatments that are effective for patients, helping support more informed decisions in cancer care.
Powered by Arizona’s Bioscience Ecosystem:
Arizona’s rapidly growing bioscience ecosystem has been a strong foundation for its oncology-focused mission. The state’s collaborative research environment, academic strengths, and expanding life sciences network have enabled meaningful partnerships and access to exceptional talent. Being part of Arizona’s innovation community & working alongside organizations like AZBio has supported their efforts to advance cancer research and translate scientific discoveries into real-world impact.
Looking Ahead
Looking ahead, they are excited to expand the application of their epigenomic platform in oncology research and clinical development. Their focus includes advancing their technology, strengthening strategic collaborations, and accelerating the translation of epigenetic insights into new cancer diagnostics. As cancer care continues to move toward precision medicine, they are motivated to play a role in shaping more effective, individualized treatments for patients and in advancing cancer diagnostics.
For a limited time, the EPISEEK-MCED test can be ordered directly through the Precision Epigenomics website (precision-epigenomics.com) —simply enter discount code 384FNF at checkout to take advantage of this exclusive offer.